Drug Trial Radar · NCT06712810
Q702 for the Treatment of Patients With Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Aug 27, 2025
Primary completion
Sep 15, 2030
Study completion Sep 15, 2030
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Histiocytic Sarcoma
- Malignant Histiocytosis
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Follicular Lymphoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelofibrosis
- Recurrent Small Lymphocytic Lymphoma
- Recurrent Waldenstrom Macroglobulinemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Erdheim-Chester Disease
- Refractory Follicular Lymphoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Myelodysplastic Syndrome
- Refractory Myelofibrosis
- Refractory Small Lymphocytic Lymphoma
- Refractory Waldenstrom Macroglobulinemia
- Rosai-Dorfman-Destombes Disease
- Primary Central Nervous System Lymphoma
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Erdheim-Chester Disease
- Recurrent Fibroblastic Reticular Cell Sarcoma
- Recurrent Histiocytic Sarcoma
- Recurrent Interdigitating Dendritic Cell Sarcoma
- Recurrent Rosai-Dorfman-Destombes Disease
- Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
- Refractory Fibroblastic Reticular Cell Sarcoma
- Refractory Histiocytic Sarcoma
- Refractory Interdigitating Dendritic Cell Sarcoma
- Refractory Rosai-Dorfman-Destombes Disease
Interventions
Axl/Mer/CSF1R Inhibitor Q702Drug
Given PO
Biospecimen CollectionProcedure
Undergo blood and urine sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy and aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy and aspiration
Computed TomographyProcedure
Undergo CT scan
Magnetic Resonance ImagingProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET scan
Survey AdministrationOther
Ancillary study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicityTime frame: Up to 3 years
- Overall response rateTime frame: Up to 3 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.